• 1
    National Cancer Institute of Canada. Canadian cancer statistics 2006. Available at URL: Accessed January 8, 2007.
  • 2
    Chu KC, Tarone RE, Kessler LG, et al. Recent trends in the US breast cancer incidence, survival and mortality rates. J Natl Cancer Inst. 1996; 88: 15711579.
  • 3
    Parkin DM, Bray FI, Ferlay F, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74108.
  • 4
    Hortobagyi GH. Treatment of breast cancer. N Engl J Med. 1998; 339: 974984.
  • 5
    Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and US breast cancer deaths down 25% in year 2000 at ages 20–69 years [letter]. Lancet. 2000; 355: 1822.
  • 6
    Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 17841792.
  • 7
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998; 352: 930942.
  • 8
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Lancet. 1998; 351: 14511467.
  • 9
    Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol. 1996; 14: 20002011.
  • 10
    Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate following tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000; 18: 13991411.
  • 11
    Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999; 17: 14131424.
  • 12
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783792.
  • 13
    O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20: 28122823.
  • 14
    Jones SE, Erban B, Overmoyer GT, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005; 23: 55425551.
  • 15
    Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000. Cancer. 2004; 100: 4452.
  • 16
    Arveux P, Grosclaude P, Reyrat E, et al. Breast cancer survival in France: a relative survival analysis based on 68,449 cases treated in the 20 French comprehensive cancer centres between 1980 and 1999 [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 3437a.
  • 17
    Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006; 24: 50915097.